Effects of Transforming Growth Factor-Beta 1 and Vascular Endothelial Growth Factor 165 Gene Transfer on Achilles Tendon Healing

Yu Hou,ZeBin Mao,XueLei Wei,Lin,LianXu Chen,HaiJun Wang,Xin Fu,JiYing Zhang,Changlong Yu
DOI: https://doi.org/10.1016/j.matbio.2009.04.007
IF: 10.447
2009-01-01
Matrix Biology
Abstract:Repaired Achilles tendons typically take weeks before they are strong enough to handle physiological loads. Gene therapy is a promising treatment for Achilles tendon defects. The aim of the present study was to evaluate the histological/biomechanical effects of Transforming growth factor-beta 1 (TGF-beta 1) and vascular endothelial growth factor 165 (VEGF(165)) gene transfer on Achilles tendon healing in rabbits. Bone Marrow-Derived Mesenchymal Stem Cells (BMSCs) were transduced with adenovirus carrying human TGF-beta 1 cDNA (Ad-TGF-beta 1), human VEGF(165) cDNA (Ad-VEGF(165)), or both (PIRES-TGF-beta 1/VEGF(165)) Viruses, no cDNA (Ad-GFP), and the BMSCs without gene transfer and the intact tendon were used as control. BMSCs were surgically implanted into the experimentally injured Achilles tendons. TGF-beta 1 distribution, cellularity, nuclear aspect ratio, nuclear orientation angle, vascular number, collagen synthesis, and biomechanical features were measured at 1, 2, 4, and 8 weeks after surgery. The TGF-beta 1 and TGF-beta 1/VEGF(165) co-expression groups exhibited improved parameters compared with other groups, while the VEGF(165) expression group had a negative impact. In the co-expression group, the angiogenesis effects of VEGF(165) were diminished by TGF-beta 1, while the collagen synthesis effects of TGF-beta 1 were unaltered by VEGF(165). Thus treatment with TGF-beta 1 cDNA-transduced BMSCs grafts is a promising therapy for acceleration and improvement of tendon healing, leading to quicker recovery and improved biomechanical properties of Achilles tendons. (C) 2009 Elsevier B.V. All rights reserved.
What problem does this paper attempt to address?